Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane

Abstract

Rationale:Within a rapidly expanding therapeutic armamentarium, the combination of everolimus (Eve) plus exemestane (Exe) utility needs to be reinstated in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC).Patient concerns:We herein report on a patient affected by HR+ HER2- MBC treated with radical surgery after neoadjuvant chemotherapy, who relapsed early on adjuvant tamoxifen, progressed rapidly on first line anastrozole, and failed treatment with third line capecitabine.Diagnoses:Metastatic luminal breast cancer progressed under standard endocrine therapy and chemotherapy.Interventions:Third line with Eve plus Exe was given after chemotherapy.Outcomes:Patient experienced a 5-year progression free interval.Lessons:Eve plus Exe remains a valid option in HR+HER2- MBC.